Trials / Unknown
UnknownNCT04305704
Coated Mongolian Aneurysm Treatment Study 2
Clinical Evaluation of the p64 MW HPC and the p48 MW HPC Flow Diverters in an Observational Registry
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 90 (estimated)
- Sponsor
- Phenox GmbH · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess safety and effectiveness of the p64 MW HPC or p48 MW HPC Flow Modulation Device under prasugrel.
Detailed description
Title: Observational Registry With p64 MW HPC in Unruptured Anterior Circulation Aneurysms Under prasugrel Purpose: To assess safety and effectiveness of p64 MW HPC or p48 MW HPC under prasugrel in consecutive patients with unruptured anterior circulation aneurysms. Follow-up intervals: Independent follow-ups (after 3 to 6 months and after 12 months and after 24 months) according to site specific standard.
Conditions
Timeline
- Start date
- 2020-02-08
- Primary completion
- 2023-02-01
- Completion
- 2023-12-30
- First posted
- 2020-03-12
- Last updated
- 2022-04-26
Locations
1 site across 1 country: Mongolia
Source: ClinicalTrials.gov record NCT04305704. Inclusion in this directory is not an endorsement.